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Background: To clarify the implications of cell-free nucleic acids (cfNA) in the plasma in neoplastic disease, it is
necessary to determine the kinetics of their release into the circulation.
Methods: To quantify non-tumor and tumor DNA and RNA in the plasma of tumor-bearing rats and to correlate
such levels with tumor progression, we injected DHD/K12-PROb colon cancer cells subcutaneously into syngenic
BD-IX rats. Rats were sacrificed and their plasma was analyzed from the first to the eleventh week after inoculation.
Results: The release of large amounts of non-tumor DNA into plasma was related to tumor development from its early
stages. Tumor-specific DNA was detected in 33% of tumor-bearing rats, starting from the first week after inoculation
and at an increasing frequency thereafter. Animals that were positive for tumor DNA in the plasma had larger tumors
than those that were negative (p = 0.0006). However, the appearance of both mutated and non-mutated DNA
fluctuated with time and levels of both were scattered among individuals in each group. The release of non-tumor
mRNA was unaffected by tumor progression and we did not detect mutated RNA sequences in any animals.
Conclusions: The release of normal and tumor cfDNA into plasma appeared to be related to individual-specific factors.
The contribution of tumor DNA to the elevated levels of plasma DNA was intermittent. The release of RNA into plasma
during cancer progression appeared to be an even more selective and elusive phenomenon than that of DNA.
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The presence of large quantities of cell-free nucleic acids
(cfNA) in the serum and plasma of cancer patients was
first reported several decades ago and was later verified
for a variety of tumors (for review, see ref. [1]). In
addition, it has been repeatedly demonstrated that some
cfNA originate in tumors [2-4].
The presence of cfNA in plasma has been analyzed for
its potential prognostic value in the diagnosis and
management of cancer (for reviews, see refs. [1,5]).
Analyses have been based on both qualitative and quanti-
tative investigations of cfNA and, in particular, of cell-free
DNA (cfDNA). However, the diversity of patients, tumors
and laboratory techniques involved in such studies has
resulted in divergent results. Thus, in spite of many
apparently encouraging reports, the analysis of cfNA in
plasma has not yet been translated into clinical practice.* Correspondence: doloresg@sescam.jccm.es
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distribution, and reproduction in any mediumLevels of cfDNA in plasma have been examined in
cancer patients [4,6-10] and in tumor-bearing animals
[4,8,11-15] but the results have been heterogeneous with
respect to correlations of the levels of such DNA with
tumor stage, location, size and/or response to therapy.
Nonetheless, Diehl et al. proposed that quantitation of
circulating mutant DNA, as a method for noninvasive
monitoring of the course of therapy, might be useful in
patients with metastatic colorectal cancer [4].
Quantitation of total cfDNA (both mutated and non-
mutated) in plasma is easier than quantitation of tumor
DNA in plasma, and the former has been proposed as a
surveillance tool for cancer [9,16] and, even, for confirm-
ation of the presence of primary tumors [9]. However, levels
of total cfDNA in plasma do not appear to be useful for
diagnostic screening [17,18], perhaps because overlapping
concentrations of cfDNA are found in healthy individuals
and in individuals affected by other pathological processes,
for example, inflammation and trauma [1]. In spite of such
limitations, some authors have suggested that accuratentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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patients, once a cutoff value has been established, might
be a valuable tool for prognostic stratification [19] and
for discrimination between patients with disease and
unaffected individuals, and might be a useful strategy
for early detection [20].
Non-tumor cfDNA has also been examined in both
human and animal models [6-8,11,19]. In a previous
study, we found that large amounts of non-tumor DNA
were released during all stages of tumor progression in rats
and, in particular, at early stages [11]. Our findings support
the hypothesis that active interactions occur between
tumor cells and non-tumor cells and are associated with
the release of cfDNA during tumorigenesis.
Subsequent to the discovery of cfDNA in plasma,
cell-free RNA (cfRNA) was also found in the plasma of
cancer patients [21,22]. In theory, cfRNA should be
much more fragile than cfDNA and should be more
susceptible to degradation. Moreover, it has been
reported that levels of ribonuclease are elevated in the
serum of patients with pancreatic cancer [23]. However,
cfRNA has been detected in plasma from patients with
malignant melanoma [22], breast cancer [24], colon
cancer [25,26], and gastric cancer [27], among others.
Indeed, cfRNA has been proposed as a promising mar-
ker of cancer. By contrast, the authors of a recent study
have suggested that detection of tumor-specific cfRNA
is not a reliable tool for monitoring disease status in
patients with neuroblastoma [28]. Nonetheless, in spite
of the presence of degradative enzymes, not only is
cfRNA present in plasma but it is also sufficiently in-
tact to allow analysis by reverse transcription-PCR
(RT-PCR; for review, see ref. [1]).
The kinetics of the release of cfNA into the bloodstream
remain poorly understood and new approaches are needed
since such kinetics might be critical to the interpretation of
the variety of results obtained in previous studies in
humans. The use of animal models for the relevant kinetic
analyses is advantageous because of the uniformity of
animals and tumors that might be expected to eliminate
confounding factors.
The goal of the present study was to quantify, simultan-
eously, both tumor and non-tumor DNA and RNA in the
plasma of tumor-bearing rats during tumor progression,
from one week after the inoculation of tumor cells to the
development, eleven weeks later, of metastases.
Materials and methods
Cell culture
We used DHD/K12-PROb cells (rat colon cancer cells; also
called DHD/K12-TRb cells; European Collection of Cell
Cultures no. 90062901; referred to as DHD cells herein) as
malignant cells. DHD cells harbor a point mutation
(G12D) in the k-ras oncogene [29]. Detection of thismutation during our analyses was considered equivalent
to the detection of tumor DNA.
Cells were cultured in monolayer in a mixture of DMEM
and Ham’s F10 (1:1, v/v; Gibco-BRL, Life Technologies
Ltd., Paisley, Scotland), supplemented with 10% fetal bovine
serum (Gibco-BRL) and gentamycin (0.005%; Gibco-BRL).
Cells were passaged after dispersion in 0.125% trypsin
in EDTA.
Animals
We used both male and female BD-IX rats. They were
taken from a colony established at the authors’ animal
facility from founders purchased from a commercial
breeder (CRIFFA, Barcelona, Spain). Breeding was
performed in compliance with European Community
Directive 86/609/CEE and Spanish law (Real Decreto
1201/2005) for the use of laboratory animals, which were
the laws in force at the time of the animal experiments.
The animal cancer model and the procedure for blood
sampling were approved by the Animal Experimentation
Ethics Committee of the University of Castilla-La Mancha,
Spain (approval no. 0804.02). Personnel who took care of
animals had been appropriately trained and accredited by
the regional government.
As recommended by the Federation of European
Laboratory Animal Science Associations (FELASA),
rats in the animal facility were tested periodically to
ensure that the colony remained free of pathogens.
From birth to the end of the experiments, all rats
had unlimited access to water and standard rat chow
(2014 Teklad Global; Harlan Laboratories, Indianapolis,
IN, USA). At the beginning of the experiments, rats were
six to eight weeks old.
Implantation of tumors and design of experiments
Tumors were generated in the thoracic region by unilateral
subcutaneous injection of DHD cells into the right side of
the chest. Cells were trypsinized, washed, and resuspended
in phosphate-buffered saline (PBS). Then 0.25 ml of this
suspension, containing 1 x 106 cells, was injected per rat.
After injection, each rat was randomly assigned to one of
six groups. Groups were designated according to the time
between the subcutaneous injection of cells and euthanasia,
as follows (numbering of groups corresponds to numbers
of weeks after injection): group 1, sacrificed one week after
injection (n = 16); group 3, sacrificed three weeks after
injection (n = 13); group 5, sacrificed five weeks after injec-
tion (n = 15); group 7, sacrificed seven weeks after injection
(n = 16); group 9, sacrificed nine weeks after injection
(n = 16); and group 11, sacrificed eleven weeks after
injection (n = 14). Each group was composed of male
and female animals in similar proportions.
Animals were inspected daily by the veterinarian of
the animal facility. The body weight and the growth of
Figure 1 Sequences of the k-ras gene that were amplified in
the present study. A) Sequence of genomic DNA (gDNA). B)
Sequence of cDNA. Capital letters, Exon sequences; discontinuously
underlined letters, sequences of the primers; underlined letters,
sequences of fluorescent hybridization probes; shaded letters,
sequence of the PNA probe.
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weekly. The greatest diameter of each tumor was measured
with electronic calipers. Our previous experience with this
model [11,29-31] demonstrated that higher-frequency
analysis is unnecessary. The protocol for handling of
tumor-bearing animals was designed according to
recommendations for ethical cancer research [32].
In addition, we included a group of healthy BD-IX
rats (n = 7), from which blood samples were taken and
processed in the same way as those from tumor-bearing
animals.
Collection of blood and tissue samples
On the schedule indicated above, rats were anesthetized
with an intraperitoneal injection of a mixture of keta-
mine (75 mg/kg) and xylazin (10 mg/kg). Then blood
(approximately 4.0 to 4.5 ml per rat) was withdrawn by
cardiac puncture and a lethal dose of sodium thiopental
was administered intracardially immediately afterwards. All
samples of blood were collected in tubes with EDTA and
subjected to centrifugation (1,800 x g, 10 min, 4°C). Plasma
was collected and subjected to a second centrifugation at
3,000 x g for 10 min. The plasma samples were divided
into aliquots and stored at -80°C prior to extraction of
DNA and RNA.
Lungs were inspected visually for the presence or absence
of pulmonary metastases, which was recorded.
Extraction of cfDNA and cfRNA from plasma samples
DNA was extracted from 240-μL samples of plasma with a
commercial kit (NucleoSpinW Plasma XS; Macherey-Nagel,
Düren, Germany), according to the instructions from the
manufacturer. DNA samples were stored at -20°C.
RNA was extracted from 1-ml samples of plasma by a
three-step procedure. First, cell-free nucleic acids (cfNA)
were extracted with a commercial kit (QIAmp UltraSens
Virus; Qiagen, Hilden, Germany). Then samples were
subjected to incubation with DNase I (Qiagen) for 10 to
15 min. Finally, total RNA was treated with the RNeasyW
MinEluteW Cleanup kit (Qiagen) and samples of RNA
were stored in RNase-free tubes at -20°C.
Analysis of the purity of cfRNA and reverse transcription
To ensure the absence of DNA from the samples of
RNA, we performed PCR to amplify a 165-bp sequence
of the rat k-ras gene. The forward primer for PCR
(sequence: 5'-ccctttacaaattgtacataga-3’) hybridized to an
intronic sequence such that any observed amplification
would be due to the presence of k-ras DNA.
Reverse transcription was performed with a commercial
kit (Transcriptor High Fidelity cDNA Synthesis; Roche
Diagnostics GmbH, Mannheim, Germany), using a
protocol based on the use of random hexameric primers
and the instructions from the manufacturer.Amplification and quantitation of cell-free nucleic acids in
plasma samples by real-time PCR
DNA samples [both genomic DNA (gDNA) and cDNA]
were analyzed by two real-time PCRs with fluorescent
hybridization probes to amplify, respectively, total
(mutated and non-mutated) k-ras sequences and exclu-
sively mutated k-ras sequences. In the latter case, we used a
peptide nucleic acid (PNA) probe, as a PCR-clamp, to sup-
press the amplification of the wild-type k-ras sequence so
that only mutated k-ras sequences would be amplified.
When no mutated k-ras was detected, we assumed that
amplification of total DNA corresponded to the amplifica-
tion of non-mutated DNA only. Samples in which mutated
DNA was detected were excluded from the analysis of
levels of non-mutated DNA.
For both sets of real-time PCRs, we used the same
set of primers to amplify a specific fragment of exon 1 of
the k-ras gene. For gDNA, we amplified a 165-bp sequence
(Figure 1-A) with the primers forward, 5´-aaggcctgct
gaaaatgactg-3’; and reverse, 5’-ccctttacaaattgtacataga-3’
(discontinuously underlined letters in Figure 1-A). For
cDNA, we amplified a 125-bp fragment (Figure 1-B)
with the same forward primer and the reverse primer
5’-ctctatcgtaggatcatattcatc-3’ (complementary to the
last stretch of discontinuously underlined letters in
Figure 1-B).
We used two hybridization probes for detection and
quantitation of both total and mutated gDNA. One of
these probes, the sensor probe, was designed to be
complementary to the point mutation (GGT→GAT) in
the k-ras oncogene (codon 12) that is found in DHD
cells. The sensor probe was labeled at the 5’ end with
LC-Red705 dye and phosphorylated at the 3’ end to yield
the following sequence: 5’-LC-Red705-ttgcctacgccatcagc
tccaa-P-3’ (first stretch of underlined letters in Figure 1).
We proved previously that this probe also hybridizes with
non-mutated DNA templates. The sequence of the anchor
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(F1), was 5´-catccacaaagtgattctgaattagctgtatcgtcaaggcact-
F1-3’ (complementary to the last stretch of underlined
letters in Figure 1-A). For the detection and quantitation
of cDNA we used the same sensor probe and the anchor
probe 5’-cacaaagtgattctgaattagctgtatcgtcaaggcac-F1-3’
(complementary to the last stretch of underlined letters in
Figure 1-B). This probe hybridizes only with exonic
sequences. Probes were manufactured by TIB MOBIOL
(Berlin, Germany).
For the second amplification by PCR, designed to detect
mutant k-ras exclusively, we added a PNA oligomer that
encompassed codons 10 to 14 of exon 1 of the k-ras gene
and had the sequence 5´-NH-cctacgccaccagctcc-CONH-3’
(complementary to shaded letters in Figure 1). This probe
was obtained from Panagene (Daejeon, Korea).
For both sets of PCRs, we used an LC Fast Start DNA
MasterPLUS Hyb Probes kit that included FastStart Taq
DNA polymerase, reaction buffer, magnesium chloride and
deoxynucleotide triphosphate mixture (Roche Diagnostics
GmbH). The reaction mixture, with a total volume of 20 μl,
contained a minimum of 2 ng of template gDNA in a
volume of 2 μl or a minimum of 5 ng of template cDNA
in a volume of 5 μl. It also contained 0.5 μM each primer,
0.15 μM sensor probe, 0.3 μM anchor probe and 5 mM
MgCl2. For detection of mutated k-ras, PNA was added at
a final concentration of 1 μM. For detection of mutated
cDNA the procedure was similar to that described for
the detection of non-mutated cDNA sequences with
the exception that the volume of cDNA in the reaction
mixture was 3 μl.
In all amplification experiments, DNA from DHD cells
and water were included as positive and negative controls,
respectively. gDNA or cDNA from the plasma of healthy
animals was also included as a positive control in amplifica-
tions without the PNA probe and as a negative control in
the case of PCR clamping.
We performed all PCRs with the LightCyclerW System
(Roche Diagnostics), using LightCyclerW Software
(version 3.5). Samples were placed in capillary tubes
and subjected to initial denaturation by incubation at 95°C
for 10 sec. Then amplification was allowed to proceed for
50 cycles of denaturation, annealing and extension. The
first step in the cycle was incubation for 2 sec at 95°C. The
annealing incubation was allowed to proceed for 7 sec at
53°C in the case of gDNA and for 10 sec at 58°C in the
case of cDNA. Finally, extension was allowed to proceed
for 15 sec at 72°C. During the second incubation
(annealing step), fluorescence was monitored at 705 nm
(F3 channel in the LightCyclerW system).
For detection of mutated k-ras, we included an
additional incubation (70°C, 10 sec) between the
denaturation and the annealing steps, for the binding
of PNA.Each reaction was performed in triplicate. We generated
four standard curves for the quantitation of, respectively,
non-mutated and mutated 165-bp k-ras sequences, and
non-mutated and mutated 125-bp k-ras sequences. In this
way we were able to quantify mutated and non-mutated
DNA and RNA (cDNA). Each curve was created by
plotting the logarithm of the amount of DNA against
the threshold cycle number. The amounts of gDNA or
cDNA in samples to be analyzed were determined from
the appropriate standard curves.
The amounts obtained by the above-described
method were recalculated to generate concentrations
(number of DNA fragments/ml of plasma) using the
following formulas:
– For quantitation of plasma DNA: [(Quantity of gDNA
obtained by PCR in fg/ Molecular mass of the
sequence in fg) / Volume of gDNA template in the
PCR reaction in μl] x (Total volume of gDNA at the
end of the extraction from plasma in μl / Volume of
plasma used for DNA extraction in ml).
– For quantitation of plasma RNA: [(Quantity of
cDNA obtained by PCR in fg/ Molecular mass of
the sequence in fg) / Volume of cDNA template in
the PCR reaction in μl] × (Total volume of cDNA at
the end of the RT reaction in μl / Volume of plasma
used for RNA extraction in ml).
For detection of mutated gDNA or cDNA, samples were
subjected to two identical consecutive amplifications by
PCR with the PNA probe. A plasma sample was considered
positive when at least one replicate of the two PCRs yielded
the mutated k-ras sequence.
Assessment of the sensitivity of the PCR-based
techniques for detection of mutated k-ras sequences
We evaluated the sensitivity of the method for detection
of the k-ras mutation by diluting DNA from DHD cells,
which carry the G12D mutation, with DNA extracted from
the plasma of healthy animals. We made serial dilutions,
from 1:10 to 1:1000. The 1:10 mixture contained 1 ng of
mutant DNA and 10 ng of wild-type DNA. Similarly, we
made serial dilutions of RNA from DHD cells with RNA
extracted from the plasma of healthy animals.
Statistical analysis
Comparisons of means were made by Student’s t-test for
normal distributions and by the Kruskal-Wallis tests for
non-normal distributions. A p-value of less than 0.05
was accepted as evidence of statistical significance.
Qualitative variables were compared using the χ2 test
and Fisher’s exact test when any frequency was less than
5. Two-tailed p-values of less than 0.05 were considered
evidence of statistical significance.
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RNA in the plasma and (i) tumor size and (ii) the presence
of metastasis were determined by Pearson correlation ana-
lysis. We also analyzed the relationship between quantities
of DNA and RNA. Statistical analyses were performed
with StatPlusW version 2009 (AnalystSoft) and OpenEpi




Tumors were detectable in rats from the first week after
inoculation of DHD cells and grew at an apparently
uniform rate for the duration of the experiment (Figure 2).
There were no statistically significant differences between
tumors in male and female rats.
Macroscopic observations
No metastases were observed in the abdominal tissues
of any of the rats; metastases were only found in the
lungs and lymphatic tissues. Lung macrometastases were
detected in five animals in group 7 (5/16; 31%), in eight
animals in group 9 (8/16; 50%), and in nine animals in
group 11 (9/14; 64%). In male rats, the presence of lung
macrometastases was slightly more frequent than in
females (p = 0.049).
Analysis of plasma DNA by real-time PCR
First, we assessed the sensitivity of the method for detection
of a mutation in the k-ras gene by dilution experiments
with various amounts of mutant DHD DNA and wild-type
DNA from rat plasma. The clamped probe assay detected
mutated DNA even when there was a 100-fold excess of
wild-type plasma DNA.
DNA was extracted from plasma from all animals and
analyzed. Tumor DNA (mutated k-ras sequences) was
found in three of the plasma samples from animals in
group 1 (3/16), in one in group 3 (1/13), in three in group 5
(3/15), in eight in group 7 (8/16), in nine in group 9Figure 2 Growth of tumors in rats after subcutaneous injection of DH
(±S.D.) for all animals examined.(9/16), and in six in group 11 (6/14; Figure 3). Thus,
we detected tumor DNA in plasma of 30 out of the
90 tumor-bearing animals in the study (33%), and, in
particular, we detected tumor DNA in 11 of the 22
animals that had lung macrometastases (50%). However,
the relationship between the detection of mutated DNA in
plasma and the presence of metastases was not statistically
significant (p = 0.07).
The presence of k-ras mutated sequences in primary
tumors and lung metastases from rats injected with
DHD cells was confirmed in previous studies [31].
Nonetheless, we tested lung metastases from five rats
whose plasma samples were negative for the detection of
mutated k-ras sequences. After amplification by PCR with
the PNA probe, we detected such mutated sequences in
all five samples.
The mean tumor diameter in animals in which tumor
DNA was detected in plasma was 3.4 ± 1.7 cm (n = 30),
whereas in animals in which no tumor DNA was detected
in plasma the mean diameter was 2.1 ± 1.6 cm (n = 60).
This difference was statistically significant (p = 0.0006).
The concentration in plasma of the mutated k-ras
sequence ranged from 1.8 × 102 to 1.6 × 106 fragments/ml
of plasma (2.1 × 105 ± 3.5 × 105 fragments/ml; mean ± s.d.;
n = 29). In one animal in group 7 (no. 7-5), the concentra-
tion was very high, namely, 1.9 × 108 fragments/ml of
plasma. Since this concentration exceeded the mean value
by three orders of magnitude, it was excluded from the
statistical analyses of levels of tumor DNA. Statistical
comparisons between groups did not reveal any statisti-
cally significant differences. The means of values obtained
from each group are shown in Figure 4.
In the samples of plasma in which no mutated DNA
was detected, the first amplification of total DNA
(without the PNA probe) was considered to correspond to
both the amplification and the quantitation of non-
mutated DNA.
The mean concentrations of non-mutated k-ras
sequences in plasma from healthy animals ranged fromD cells. Values shown are mean maximum diameters of tumors
Figure 3 Histograms showing the percentage, in each group (as indicated by time in weeks), of animals that was positive for tumor
(mutated) DNA in plasma.
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7.7 × 104 fragments/ml; n = 7). In samples from tumor-
bearing rats, the concentrations ranged from 1.5 x 103 to
5.8 × 106 fragments/ml of plasma (4.7 × 105 ± 1.2 × 106
fragments/ml; n = 60). The means of values obtained from
each group are shown in Figure 4.
Overall, levels of non-mutated DNA in all tumor-
bearing animals together were higher than those in
healthy animals, and the difference was statistically
significant (p = 0.02). However, there was no statistically
significant difference between the group of healthy
animals and each group of tumor-bearing rats. The
lowest mean value was found in group 7, although there
was no statistically significant difference with respect to
the values in other groups. The standard deviations in
the concentrations of non-tumor DNA in tumor-bearing
rats were higher than those of tumor DNA in these rats.Figure 4 Amounts of DNA and RNA, as detected by real-time PCR, in
of tumor progression. Values are means of results from all rats in each gr
DNA, and of rat no. 9-10, in the case of levels of non-tumor RNA, as discusPearson correlation analysis showed that, overall, the
concentrations of both mutated and non-mutated k-ras
sequences in plasma were unrelated to tumor size.
However, concentrations of mutated k-ras sequences
were slightly higher in animals whose tumors were equal
to or greater than 2 cm in diameter than in animals with
tumor diameters of less than 2 cm (p = 0.045).
Student’s t-test showed that there were no significant
differences in the concentrations of both mutated and
non-mutated k-ras sequences between animals with and
without macrometastases.
Quantitation of plasma RNA by real-time PCR
We were able to analyze RNA in only some of the animals
since volumes of plasma were not always sufficient for all
analyses. Specifically, we analyzed plasma RNA from eight
animals each in groups 1, 3 and 9; from seven animalsplasma from healthy and tumor-bearing rats at different stages
oup with the exception of rat no. 7-5, in the case of levels of tumor
sed in the text.
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(i.e., from 44 tumor-bearing rats in total), and from
five healthy animals.
In seven plasma samples (15%), no k-ras cDNA was
detected. There was one such negative sample in each of
groups 1, 3, 7 and 9 and in the group of healthy rats;
there were two negative samples in group 5 and none in
group 11.
We failed to find mutated RNA sequences in any of
the plasma examined. Thus, the first amplification without
the PNA probe was considered to correspond to both the
amplification and the quantitation of non-mutated cDNA.
We assessed the sensitivity of the method for detection of
mutated sequences of k-ras RNA by dilution experiments
with various amounts of mutant DHD RNA and wild-type
plasma RNA. The assay detected mutated RNA sequences
even when there was a 1000-fold excess of wild-type
plasma RNA.
In the samples from healthy animals, the concentrations
of non-mutated k-ras cDNA ranged from 610 to 3,100
fragments/ml of plasma (1,400 ± 1,200 fragments/ml;
n = 4). In samples from tumor-bearing rats, the concentra-
tions ranged from 23 to 6,100 fragments/ml of plasma
(1,400 ± 1,400 fragments/ml; n = 36). The mean values
obtained from each group are shown in Figure 4. The result
for one animal in group 9 (no. 9-10) was excluded from the
analysis since the concentration (150,000 fragments/ml)
was two orders of magnitude higher than that for the
animal that, otherwise, gave the highest result. There
was no statistically significant difference between healthy
and tumor-bearing animals.
Pearson correlation analysis showed that, overall, the
concentration of non-mutated RNA was unrelated to
tumor size, and Student’s t-test showed that there was no
significant difference between animals with and without
macrometastases.
The mean concentration of non-mutated RNA in
plasma was lower than that of non-mutated DNA in
plasma in both tumor-bearing (p = 0.004) and healthy
rats (p = 0.04).
Discussion
The clinical value and role of cfNA in plasma of cancer
patients remain to be clarified (for review, see ref. [1]).
However, release of cfNA from tumors might be directly
involved in the development of metastases, as proposed
in the “Genometastasis Hypothesis” [30,33], and it has
been reported that plasma DNA can, indeed, transfect
and oncogenically transform cultured cells [34].
The kinetics of changes in the concentration of cfNA
in plasma during cancer progression have not been fully
defined and previously reported results are non-uniform.
Therefore, in the present study, we used a heterotopic rat
model of colon cancer, in which tumors were generatedsubcutaneously, and real-time PCR to quantify non-
mutated and mutated DNA and RNA sequences in
plasma from both healthy and tumor-bearing animals
as tumors developed. In a similar previous study, we
focused on the release of non-tumor DNA, using a
similar method [11]. In the present study, we increased
the number of animals examined in order to focus on
mutated DNA, and we used real-time RT-PCR to detect
and quantify RNA fragments in plasma.
We detected non-mutated k-ras sequences in plasma
from all healthy and cancerous animals, and we detected
mutated k-ras sequences in 33% of all tumor-bearing rats
examined. Concentrations both of tumor and non-tumor
DNA in plasma fluctuated as tumors developed.
The results of quantitation of non-mutated k-ras
sequences confirmed those in our previous study [11].
Overall, we found that concentrations of circulating
non-mutated k-ras sequences were significantly higher in
tumor-bearing animals than in healthy animals (p = 0.02).
However, when we compared, individually, each of the six
groups of tumor-bearing rats with healthy animals, there
were no statistically significant differences as a consequence
of the high standard deviations in the groups of tumor-
bearing rats. Such fluctuations and scattering of values,
which appear to be inherent to the release of DNA into the
bloodstream, might be one of the reasons for the difficulties
encountered in efforts to establish standard cut-off levels
for diagnosis and prognosis in a clinical setting.
Most previous human studies have found similarly
elevated levels of total DNA [9,16] and/or non-tumor
DNA [6,7] in plasma from cancer patients, but relationships
between such levels and tumor size and other clinical
parameters remain contradictory [7,9,35-38]. It is possible
that the kinetics of release of cfDNA might be specific, to a
first approximation, to each kind of cancer. For example,
two studies, using identical methods, showed that levels of
cfDNA in plasma from patients with esophageal cancer
were higher than those in patients with gastric cancer.
Moreover, in the latter patients, levels were associated with
tumor stage, which was not the case in the patients with
esophageal cancer [6,7].
In the present study, diameters of tumors were not
correlated with levels of non-tumor DNA in plasma. In
fact, while tumors were growing at a steady rate (Figure 2),
concentrations of non-mutated DNA in plasma fluctuated,
with a peak at the early stage of tumor progression (three
weeks after the inoculation of cells; Figure 4). The timing
of this release of non-tumor cfDNA was very similar to
that reported some years ago in the same animal model
[11], and the present results also support the hypothesis
that plasma levels of non-mutated DNA might be a
particularly useful diagnostic tool at the early stages of
tumor development. We do not know why the concen-
tration of non-mutated DNA in plasma is significantly
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these early stages, normal and malignant cells interact
and their interactions might lead to the release of non-
tumor DNA via, perhaps, enhanced turnover of cells and
cell death or even the active release of DNA from host cells,
as demonstrated previously in cultured cells [39]. In a
recent study, the authors supported the notion that the
release of non-tumor cfDNA to the bloodstream is related
to cancer progression, since their results showed a potential
prognostic power of the quantitation of such DNA in
plasma from lung cancer patients [19].
In the present study, detection of mutated DNA in
plasma was an early event, occurring from the first week
after inoculation of cells, and both the frequency of such
detection and the levels of mutated DNA increased with
time and tumor diameter. The animals in which tumor
DNA was detected in plasma had larger tumors than
those in which it was not (p = 0.0006), and animals with
tumors of 2 cm or more in diameter had slightly higher
levels of tumor DNA in their plasma than animals with
smaller tumors (p = 0.045). However, there was no statisti-
cally significant correlation between variables. In addition,
the frequency of tumor DNA-positive plasma in animals
with metastases was only 50%, and levels of tumor DNA
in these animals were not significantly different from
those in animals without metastases. These results are in
agreement with those of previous studies of patients with
colorectal cancer, which failed to demonstrate any signifi-
cant correlation between tumor load (including metastatic
deposits) and the amount of mutant DNA in the circula-
tion [40]. Our failure to detect the mutated k-ras sequence
in half of our animals with metastases cannot be explained
by the hypothetical absence of this mutated sequence in
metastases. The presence of mutated k-ras sequences in
both the primary tumors and the lung metastases from
rats injected with DHD cells was confirmed in previous
studies [31] and, in the present study, we examined a
number of lung metastases and all yielded positive results
with respect to the detection of such mutated sequences.
The highest frequency of detection of tumor DNA in
plasma was 56% (at the ninth week after inoculation).
This relatively low frequency supports the hypothesis
that increases in concentrations of total DNA in plasma
during cancer progression are not due to DNA from
neoplastic cells, as also suggested by previous studies in
patients with breast [35] and colorectal cancer [40]. To
explain the absence or low levels of mutant DNA in
plasma after cancer has progressed, it has been proposed
that the fragments of tumor DNA are degraded more
effectively in plasma than the circulating DNA derived
from non-neoplastic cells [40]. By contrast, a recent study
of colorectal cancer patients indicated that concentrations
of total cfDNA and mutant KRAS DNA in plasma were
strongly correlated, leading the authors to postulate thatthe increasing concentrations of cfDNA in the bloodstream
of cancer patients are primarily of tumor origin [10]. The
results of the present study suggest that the contribution of
tumor DNA to the increased concentrations of plasma
DNA in cancer patients might be intermittent, and,
moreover, that DNA derived from normal and tumor
cells might behave differently in terms, for example, of
susceptibility to degradation.
In studies with animal models, some authors have
found increasing concentrations of tumor DNA in
plasma from xenografted immunodeficient mice [12-15],
with a positive correlation between concentrations of
tumor-derived DNA in plasma and the size of tumors
[12,14,15]. A similar observation was reported in CD1
mice that had been injected with CD1-derived tumor
cells and maintained for two weeks [8]. These results are
not fully confirmed by the present study since the concen-
trations that we determined were more unstable, perhaps
because of some major differences in experimental design
with respect to number of animals and duration. In the
present study, we used immunocompetent rats injected
with rat tumor cells (allografted animals), and this
experimental design results in interactions between
tumor and host cells that are probably closer to those in
human malignancy than are the interactions in immuno-
deficient animals.
With respect to the non-mutated mRNA in plasma,
concentrations were similar in healthy and tumor-
bearing rats, remaining basically unchanged during
tumor progression (Figure 4). Concentrations of mRNA
were also lower than those of non-tumor DNA in
healthy rats (p = 0.04), as well as in tumor-bearing ones
(p = 0.004).
It has been reported that concentrations of specific
RNA sequences exclusively are selectively elevated in
cancer patients. For example, levels of β-catenin mRNA
were found to be selectively elevated in plasma of patients
with colorectal carcinomas and adenomas, but levels of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA were not [41]. Note, in this context, that immu-
nostaining of β-catenin usually reveals abnormal nuclear
accumulation of this protein in tumor cells. Similarly, it
has been reported that thymidylate synthase (TS) mRNA
was detected more frequently and at higher levels in
plasma of patients with colorectal cancer than in plasma
of healthy subjects [42]. In addition, a statistically signifi-
cant correlation was found between high levels of TS in
tumors and the presence of TS mRNA in plasma [42].
Moreover, the activity of human telomere-specific reverse
transcriptase (hTERT) is elevated in most colorectal
tumors and the presence in plasma of hTERT mRNA has
been proposed as a marker for detection and monitoring
of colorectal cancer [26,43]. In the present study, mutated
k-ras mRNA sequences (derived from tumor cells) were
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suggests that the release of tumor-derived RNA into
plasma is a more elusive phenomenon than the release of
DNA and is probably restricted to overexpressed
sequences in each kind of tumor.
It has been proposed that extracellular plasma RNA is
confined to vesicle-like structures, for example, exosomes
[44,45]. Balaj et al. proposed recently that tumor microve-
sicles might contain not only elevated levels of RNA, but
also DNA, mutated and amplified oncogene sequences and
transposable elements [46]. Exosomes have been described
as particles that are able to transfer their RNA content to
cells, and it has been proposed that this RNA can be
functional in its new location [47]. Such RNA might be
related to the pro-metastatic capacity of exosomes.
However, the possibility of horizontal transfer of DNA
from such particles should not be ignored since there is
strong evidence that DNA, circulating in plasma, might
be transferred to susceptible cells, with the subsequent
oncogenic transformation of these cells [34].
Conclusions
In the present study of a homogeneous population of syn-
genic animals with a predictable malignancy, the release
of cfDNA into plasma was greater and more frequent than
that of cfRNA. The presence of detectable tumor DNA
and of high levels of non-tumor DNA in plasma was
related to the induced cancer from its early stages,
whereas the release of non-tumor RNA was unaffected by
tumor progression and the release of mutated RNA was
undetectable. Concentrations of cfDNA in plasma fluctu-
ated during tumor progression and were scattered among
individuals, suggesting that the release of cfDNA was
related to individual factors and even to the kind of DNA
(normal or tumor DNA). The release of non-tumor DNA
followed a specific time course that was predictable from
the results of previous studies in the same model, but it
would probably be very difficult to define such kinetics in
humans with a view to clinical relevance because of the
heterogeneity of individual patients and tumors, even in
cases of the same kind of cancer.
Finally, our results suggest that the release of RNA
and the release of DNA into the plasma are basically
independent phenomena. Further studies are needed to
examine whether, in spite of this independence, the two
phenomena act cooperatively in tumor progression.
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